From February 3 to 6, 2025, the highly anticipated Medlab Middle East was held as scheduled at the Dubai World Trade Center. As the premier medical laboratory exhibition, Medlab Middle East has won global acclaim for its exciting presentation of laboratory technology and innovation. Attracting nearly 20,000 professionals from more than 180 countries and regions, the event provides an excellent networking platform for diagnostic industry elites to explore cutting-edge solutions, experience breakthroughs and establish valuable business contacts. Biotest has sent a strong team to participate in the exhibition, which covers sales, R&D and marketing departments. Before the exhibition, Biotest also organized a special pre-show meeting to make detailed planning and preparation for the exhibition strategy, product display and customer communication, etc., to ensure that the company's latest technology and products could be fully demonstrated at the exhibition.

Biotest has always been committed to promoting the innovation of diagnostic products and testing technologies. At this year's MEDLAB in Dubai, Biotest focused on the FluidicNow^TM microfluidic immunoassay system. This demonstration is also the debut of FluidicNow^TM microfluidic technology in the Middle East. As the third generation of new rapid detection technology, FluidicNow^TM microfluidic has the core technology design of integrating biochip and active instrumentation system and the function of multi-item joint detection, which is applicable to whole blood samples, can be stored at room temperature, and can obtain the quantitative results within minutes, and its unique technical advantages have been widely praised and concerned by the industry, and become one of the highlights of the exhibition. In addition, Biotest also recommended the new DiaPal series of immunochromatographic readers, which are novel in design, easy to operate, powerful in function, and suitable for a wide range of rapid test reagent models on the market, and can replace the human eye for result interpretation. Biotest continues to make efforts in reagent innovation and development, and launched a series of innovative test reagents in this exhibition, including new respiratory 4 in 1 antigen rapid test kit, the new drug abuse saliva test , G6PD Rapid Test , Pertussis IgG Antibody Rapid Test and so on. The newly launched Raipid test has won the attention and favor of many customers with its excellent performance and novel design.

During the exhibition, Biotest analyzed the development trend of the international market and the real needs of customers. Through the face-to-face communication with global customers, Biotest collected many valuable suggestions on new product development and market demand. This information not only helps the company to accurately grasp the industry dynamics, but also provides important guidelines for future product innovation and market layout. Looking ahead, Biotest will always adhere to the market demand-oriented, adhering to the core concept of “scientific and technological innovation, quality-oriented”, and is committed to transforming cutting-edge technologies into efficient and reliable diagnostic solutions, as well as deepening the international cooperation to further develop and consolidate its position in the international market, and contributing more power to global health.